Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Byron Jones

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Pharmaceutical Statistics|November 4, 2006
Adaptive design: a concept whose time has comeByron Jones
Statistical Methods in Medical Research|June 23, 2005
The design of multicentre trialsValerii Fedorov, Byron Jones
Journal of the National Cancer Institute|October 9, 2008
Re: randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido: north central cancer treatment group protocol N02C3Byron Jones, Scott Haughie
Pharmaceutical Statistics|December 14, 2011
Viewpoint: observations on scaled average bioequivalenceScott D Patterson, Byron Jones
Pharmaceutical Statistics|May 4, 2007
A brief review of Phase 1 and Clinical Pharmacology statistics in clinical drug developmentScott D Patterson, Byron Jones
Biometrical Journal. Biometrische Zeitschrift|March 14, 2018
Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian-frequentist approachJohanna Mielke, Heinz Schmidli, Byron Jones
Computer Methods and Programs in Biomedicine|February 15, 2021
Model based dose personalization in clinical trialsKabir Soeny, Barbara Bogacka, Byron Jones
Pharmaceutical Statistics|February 10, 2018
Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parametersJohanna Mielke, Heike Woehling, Byron Jones
Pharmaceutical Statistics|March 21, 2012
Fitting E(max) models to clinical trial dose-response dataSimon Kirby, Phil Brain, Byron Jones
Statistics in Medicine|February 21, 2018
Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalenceWilli Maurer, Byron Jones, Ying Chen
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Pharmaceutical Statistics|November 4, 2006
Adaptive design: a concept whose time has comeByron Jones
Statistical Methods in Medical Research|June 23, 2005
The design of multicentre trialsValerii Fedorov, Byron Jones
Journal of the National Cancer Institute|October 9, 2008
Re: randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido: north central cancer treatment group protocol N02C3Byron Jones, Scott Haughie
Pharmaceutical Statistics|December 14, 2011
Viewpoint: observations on scaled average bioequivalenceScott D Patterson, Byron Jones
Pharmaceutical Statistics|May 4, 2007
A brief review of Phase 1 and Clinical Pharmacology statistics in clinical drug developmentScott D Patterson, Byron Jones
Biometrical Journal. Biometrische Zeitschrift|March 14, 2018
Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian-frequentist approachJohanna Mielke, Heinz Schmidli, Byron Jones
Computer Methods and Programs in Biomedicine|February 15, 2021
Model based dose personalization in clinical trialsKabir Soeny, Barbara Bogacka, Byron Jones
Pharmaceutical Statistics|February 10, 2018
Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parametersJohanna Mielke, Heike Woehling, Byron Jones
Pharmaceutical Statistics|March 21, 2012
Fitting E(max) models to clinical trial dose-response dataSimon Kirby, Phil Brain, Byron Jones
Statistics in Medicine|February 21, 2018
Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalenceWilli Maurer, Byron Jones, Ying Chen
Pageof 4